DBSMatchMaker : Global Uptake and Insights from the First Year of a Collaborative Deep Brain Stimulation Platform
DBSMatchMaker : Global Uptake and Insights from the First Year of a Collaborative Deep Brain Stimulation Platform
Where did the research take place?
The study site has not been established. Author addresses may differ from where the research occurred.
A plain-language reading has not been prepared for this paper yet.
Original abstract
Abstract Background DBSMatchMaker ( https://www.dbsmatchmaker.com ), launched publicly in December 2024, is a freely accessible, web‐based platform that connects clinicians treating rare genetic movement disorders with deep brain stimulation (DBS). Objective/Methods To characterize the first year of adoption and early clinical impact of DBSMatchMaker. We evaluated global uptake, usage patterns, and early insights from December 2024 to December 2025. We analyzed aggregate, deidentified submissions; required fields included genetic diagnosis and DBS target, with optional three‐point treatment response ratings. Results Forty‐one clinicians from 39 institutions across 20 countries submitted 158 unique cases spanning 58 monogenic movement disorders, most commonly GNAO1 ‐, KMT2B ‐, PANK2 ‐, ADCY5 ‐, and SGCE ‐related disorders. Among entries with outcome ratings, 84.6% reported strong or moderate benefit. The system generated 614 clinician matches, including several that led to changes in management or multicenter research case series. Conclusions Early adoption highlights global engagement and clinical utility. DBSMatchMaker serves as a living repository that lowers barriers to data sharing and supports data‐driven DBS decision‐making. © 2026 International Parkinson and Movement Disorder Society.